Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine

By Sasaki Takashi  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 708-713

Springer Publishing Company

Access to resources Recommend Favorite

A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers

By Ciuleanu T.   Diculescu M.   Hoepffner N.   Trojan J.   Sailer V.   Zalupski M.   Herrmann T.   Roth A.   Chick J.   Brock K.   Albert D.   Philip P.  

Investigational New Drugs, Vol. 25, Iss. 4, 2007-08 ,pp. : 385-390

Springer Publishing Company

Access to resources Recommend Favorite

Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

By Boér Katalin  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 681-687

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies

By Cho Cheryl   Fisher George   Halsey Joanne   Sikic Branimir  

Investigational New Drugs, Vol. 24, Iss. 2, 2006-03 ,pp. : 117-123

Springer Publishing Company

Access to resources Recommend Favorite

Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer

By Madajewicz Stefan  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 772-778

Springer Publishing Company

Access to resources Recommend Favorite